CBD for pain in hand OA/inactive PsA: - works in animal models (many things do) - other neg RCTs didn't use CBD itself - DBRCT: 12w continuous, n=136, min dropout Result: does absolutely nothing I bet big money it will be tried again & again @Joner_MD #ACR21 ABST1456 @RheumNow https://t.co/lZLVrgrKST

Dr Vela presents DB RCT on cannabidiol in hand OA and PsA. No effect seen. Abstr#1456 #ACR21 @RheumNow https://t.co/ck2eUx5Elz

The opening of #ACR21 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford). Read more.. https://t.co/m98lrjFgS4 https://t.co/vKpCEDJiyx

COVID in Rheumatologic Disease Patients: Drs. Sparks, Liew, Yazdany and Dao provide an update on data specific to COVID in rheumatologic disease patients. @jeffsparks @drdavidliew @KDAO2011 #ACR21 https://t.co/IzDIpe5IrU https://t.co/6i8C3Grw9q

apart from that, fibrosis is fascinating - as is the potential for a shared fibrotic pathway #ACR21 Antifibrotics session @RheumNow https://t.co/FXbhBx9sJ1

#ACR21 Ab#1445. RTX & #covid19 outcomes ⭐️RTX ass. w/ Upwards arrow COVID hospitalization, ICU admission, and ventilation ▶️We need huge caution in pts that have not been vax'ed before RTX 💉💉 @Rheumnow https://t.co/6UNUVhnBkI https://t.co/vHkQe9fZpI

#ACR21 Ab#1036. Rheum is often the field of uncertainty. @zach_wallace_md shows uncertainty correlates w/ depression, anxiety, sickness impact across rheum diseases ⭐️Is uncertainty something to target as intervention? @Rheumnow https://t.co/v9kbk2hCqO https://t.co/50ELS3ZQp9

So what do we do with Iberdomide data? Tough to analyze re 2nd half of yr1 and uncertainty of dose response Abst#1458 #ACR21 @RheumNow v low placebo response 35% Interesting https://t.co/JXnoJTy2tv

Among 6 CV risk algorithms, the best to predict the carotid plaque (CP) in PsA is the ACC/AHA risk score showed an AUC 0.681 (0.551-0.812), p=0.008, a cut-off point ≥4.8, sensitivity of 63.6%, and specificity of 64.4% ⭐️Prevalence CP 42.3% Abst #1315 #ACR21 @RheumNow https://t.co/hRvyjetYq3

I thought pirfenidone was just an anti-fibrotic - the spectrum of its MOA is actually fascinating @ErinWilfongMD #ACR21 Antifibrotics session, chaired by @JuliePaikMD @RheumNow https://t.co/oMZOtfAUq0